Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

China Finds Babies Deaths Not Caused by Vaccine: Xinhua

Jan. 3 (Bloomberg) -- China found that a hepatitis B vaccine produced by a Shenzhen biotechnology company didn’t cause the deaths of nine babies who received injections, the country’s food and drug agency said.

The vaccine for the liver disease made by Shenzhen Kangtai Biological Products Co. was not responsible for the deaths, the China Food and Drug Administration said on a statement on its website.

At least a dozen newborn babies have died nationwide after receiving hepatitis B shots, fueling concern about the safety of vaccines in China, the official Xinhua news agency said Dec. 31. China has been investigating links between the deaths and hepatitis B vaccines that were given as part of a national campaign to immunize against the liver condition.

Three Chinese drug producers, including Kangtai, that make about 80 percent of the nation’s hepatitis B vaccines halted output because they don’t meet new production-quality requirements, Xinhua reported yesterday. The CFDA didn’t find any quality or production problems in a check of two batches of hepatitis B vaccine produced by Kangtai that were under investigation, according to the statement. The agency didn’t say what had caused the baby deaths.

Beijing Tiantan Biological Products Co. and Dalian Hissen Bio-Pharm were among the companies that stopped production on Jan. 1, according to the news agency. Tiantan in a statement said it stopped production because it needs to move equipment in order to meet Chinese manufacturing requirements, not because of the investigation into the hepatitis B vaccinations. The company had disclosed the production halt in October. Tiantan’s stock rose as much as 8.9 percent to 21.99 yuan in Shanghai trading today.

Xinhua said the country had an inventory of more than 25 million batches of hepatitis B vaccine that meet standards apart from the Kangtai products.

Consumer Confidence

Chinese regulators have been pushing to boost consumer confidence in food and drug safety after cases of tainted baby formula, fox meat sold as mutton and thousands of dead pigs found floating in Shanghai’s main river sparked public outrage. Authorities in March elevated the China Food and Drug Administration to a ministry-level agency to strengthen supervision.

Wal-Mart Stores Inc. yesterday said it’s adding DNA tests of meat it sells in China after recalling donkey products from a local supplier that authorities said contained fox DNA.

China’s food and drug regulator on Dec. 20 suspended the use of all batches of a hepatitis B vaccine made by Kangtai pending the results of a probe into its connection with the death of four infants. It had on Dec. 13 halted use of two batches of the vaccine.

No one answered the phone at Kangtai’s general line today after two calls were made. Tiantan referred media inquiries to its parent company, China National Biotec Group. Two people who answered the phone at the group declined to be named and said that no one was available to immediately comment.

A person answering the phone at Dalian Hissen’s general line declined to be named and could not provide immediate comment.

The three companies accounted for about 80 percent of China’s hepatitis B vaccine output in January through November last year, Xinhua Weibo reported. The vaccinations were added to China’s national immunization program in 2002 and have been free for all children since 2005, according to the Atlanta-based Centers for Disease Control and Prevention.

To contact Bloomberg News staff for this story: Sarah Chen in Beijing at schen514@bloomberg.net; Natasha Khan in Hong Kong at nkhan51@bloomberg.net

To contact the editor responsible for this story: Anjali Cordeiro at acordeiro2@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.